Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.64 |
| ▸ | HTR6 | P50406 | 6/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.55 |
| ▸ | HTR1A | P08908 | 3/20 | 0.50 |
| ▸ | HTR7 | P34969 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6588798 | 0.95 | DRD2 (0.70) | DRD2HTR6KCNH2HTR1AHTR7 | |
| Oxalic Acid SCHEMBL6777204 | 0.93 | DRD2 (0.64) | DRD2HTR6KCNH2HTR7 | |
| Oxalic Acid SCHEMBL6776482 | 0.90 | DRD2 (0.64) | DRD2HTR6KCNH2HTR1AHTR7 | |
| Oxalic Acid SCHEMBL6595691 | 0.89 | DRD2 (0.81) | DRD2HTR6KCNH2HTR1A | |
| SCHEMBL6589225 | 0.88 | DRD2 (0.70) | DRD2HTR6KCNH2HTR1AHTR7 | |
| SCHEMBL6589446 | 0.84 | DRD2 (0.70) | DRD2HTR6KCNH2HTR1AHTR7 | |
| SCHEMBL6589929 | 0.83 | DRD2 (0.89) | DRD2HTR6KCNH2HTR1A | |
| Oxalic Acid SCHEMBL8134496 | 0.79 | HTR6 (0.56) | DRD2HTR6KCNH2HTR1AHTR7 | |
| Oxalic Acid SCHEMBL6590606 | 0.79 | DRD2 (0.81) | DRD2HTR1AHTR7 | |
| Oxalic Acid SCHEMBL6773628 | 0.79 | DRD2 (0.69) | DRD2HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727263-B2 | SEROTONINE REUPTAKE INHIBITOR; ANTIDEPRESSANTS; SIDE EFFECT REDUCTION | H. LUNDBECK A/S (DK) | 2004-04-27 | — | — | US | disclosed |
| US-20030018050-A1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2003-01-23 | — | — | US | disclosed |
| US-6476035-B1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2002-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018050-A1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | TPH1, HTR1A, HTR3A | DRD2 26/4885HTR6 18/4885KCNH2 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.